Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1955 1
1956 4
1957 4
1958 1
1959 2
1960 2
1961 2
1967 1
1975 1
1976 3
1977 2
1978 1
1980 1
1983 1
1987 1
1989 2
1992 2
1993 3
1994 2
1996 4
1997 3
1998 5
1999 6
2000 3
2001 9
2002 9
2003 6
2004 17
2005 20
2006 23
2007 15
2008 16
2009 19
2010 25
2011 29
2012 46
2013 36
2014 39
2015 36
2016 53
2017 60
2018 61
2019 70
2020 76
2021 102
2022 95
2023 68
2024 79
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

930 results

Results by year

Filters applied: . Clear all
Page 1
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.
de Castro G Jr, Kudaba I, Wu YL, Lopes G, Kowalski DM, Turna HZ, Caglevic C, Zhang L, Karaszewska B, Laktionov KK, Srimuninnimit V, Bondarenko I, Kubota K, Mukherjee R, Lin J, Souza F, Mok TSK, Cho BC. de Castro G Jr, et al. Among authors: lopes g. J Clin Oncol. 2023 Apr 10;41(11):1986-1991. doi: 10.1200/JCO.21.02885. Epub 2022 Oct 28. J Clin Oncol. 2023. PMID: 36306479 Free PMC article. Clinical Trial.
Caffeine intake during pregnancy and adverse outcomes: An integrative review.
Rohweder R, de Oliveira Schmalfuss T, Dos Santos Borniger D, Ferreira CZ, Zanardini MK, Lopes GPTF, Barbosa CP, Moreira TD, Schuler-Faccini L, Sanseverino MTV, da Silva AA, Abeche AM, Vianna FSL, Fraga LR. Rohweder R, et al. Among authors: lopes gptf. Reprod Toxicol. 2024 Jan;123:108518. doi: 10.1016/j.reprotox.2023.108518. Epub 2023 Dec 1. Reprod Toxicol. 2024. PMID: 38042437 Review.
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Gainor JF, et al. Among authors: lopes g. Lancet Oncol. 2021 Jul;22(7):959-969. doi: 10.1016/S1470-2045(21)00247-3. Epub 2021 Jun 9. Lancet Oncol. 2021. PMID: 34118197 Clinical Trial.
Aural Myiasis.
Rato C, Lopes G. Rato C, et al. Among authors: lopes g. N Engl J Med. 2022 Nov 24;387(21):e53. doi: 10.1056/NEJMicm2005407. Epub 2022 Nov 19. N Engl J Med. 2022. PMID: 36409505 No abstract available.
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Subbiah V, Cassier PA, Siena S, Garralda E, Paz-Ares L, Garrido P, Nadal E, Vuky J, Lopes G, Kalemkerian GP, Bowles DW, Seetharam M, Chang J, Zhang H, Green J, Zalutskaya A, Schuler M, Fan Y, Curigliano G. Subbiah V, et al. Among authors: lopes g. Nat Med. 2022 Aug;28(8):1640-1645. doi: 10.1038/s41591-022-01931-y. Epub 2022 Aug 12. Nat Med. 2022. PMID: 35962206 Free PMC article. Clinical Trial.
ASCO Global Guidelines: Methods and Opportunities.
Aziz Z, Temin S, Bachmann S, Lopes G, Fadelu T. Aziz Z, et al. Among authors: lopes g. JCO Glob Oncol. 2024 Aug;10:e2400310. doi: 10.1200/GO-24-00310. JCO Glob Oncol. 2024. PMID: 39236284 Free PMC article. No abstract available.
Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
Mok TSK, Lopes G, Cho BC, Kowalski DM, Kasahara K, Wu YL, de Castro G Jr, Turna HZ, Cristescu R, Aurora-Garg D, Loboda A, Lunceford J, Kobie J, Ayers M, Pietanza MC, Piperdi B, Herbst RS. Mok TSK, et al. Among authors: lopes g. Ann Oncol. 2023 Apr;34(4):377-388. doi: 10.1016/j.annonc.2023.01.011. Epub 2023 Jan 25. Ann Oncol. 2023. PMID: 36709038 Free article.
Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors.
Morgenstern-Kaplan D, Kareff SA, Trabolsi A, Rodriguez E, Krause H, Ribeiro JR, Tan H, Antonarakis ES, Lou E, Nagasaka M, Algaze S, Lenz HJ, Liu SV, Halmos B, Hoon DSB, Seeber A, Ma PC, El-Deiry WS, Vanderwalde AM, Lopes G. Morgenstern-Kaplan D, et al. Among authors: lopes g. Oncologist. 2024 Nov 4;29(11):e1480-e1491. doi: 10.1093/oncolo/oyae168. Oncologist. 2024. PMID: 38986529 Free PMC article.
930 results